Phase 4 Crohn's disease trials recruiting now

All Crohn's disease trials, every phase

Other phases for Crohn's disease

Phase 4 Crohn's disease trials

• A Clinical Trial of Taibowei® Adalimumab Injection in the Treatment of Chinese Pediatric Patients With Moderately to Severely Active Crohn's Disease
  NCT07564505 · Phase: Phase 4 · Ages: 6 Years to 17 Years · Sex: All (male and female) · 1 location
• A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
  NCT06045754 · Phase: Phase 4 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 48 locations
• A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
  NCT06581328 · Phase: Phase 4 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 202 locations
• A Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically
  NCT07654751 · Phase: Phase 4 · Ages: 18 Years and older · Sex: Female · 3 locations
• A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)
  NCT07310095 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Bowel Preparation for Colonoscopy Among Individuals With Crohn's and Ulcerative Colitis Disease.
  NCT06298461 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
  NCT05781152 · Phase: Phase 4 · Ages: 6 Years to 17 Years · Sex: All (male and female) · 26 locations
• Combined Immunosuppression for Pediatric Crohn's Disease
  NCT05043870 · Phase: Phase 4 · Ages: 6 Years to 18 Years · Sex: All (male and female) · 1 location
• Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.
  NCT06180382 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• Control Crohn Safe Trial
  NCT03917303 · Phase: Phase 4 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 6 locations
• De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis
  NCT07303686 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease
  NCT06520397 · Phase: Phase 4 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease
  NCT07292012 · Phase: Phase 4 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 6 locations
• Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients
  NCT06774079 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Interleukin-23 Monoclonal Antibody for Inflammatory Bowel Disease: Efficacy and Safety
  NCT07216014 · Phase: Phase 4 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 2 locations
• Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch
  NCT06864403 · Phase: Phase 4 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 5 locations
• Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD
  NCT06997965 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Optimal Care With Guselkumab in Crohn's Disease / OPTIM Study A Prospective Open Label Interventional, Multicenter Study
  NCT07616687 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease
  NCT05928039 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 20 locations
• Pharmacokinetic Infliximab Data in Pediatric Crohn's Disease
  NCT05552287 · Phase: Phase 4 · Ages: 1 Year to 15 Years · Sex: All (male and female) · 1 location
• Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients
  NCT05906576 · Phase: Phase 4 · Ages: 6 Years to 17 Years · Sex: All (male and female) · 1 location
• Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biological Therapy
  NCT05169593 · Phase: Phase 4 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 28 locations
• Stopping PPI Therapy in Inactive IBD
  NCT07691138 · Phase: Phase 4 · Ages: 16 Years and older · Sex: All (male and female) · 2 locations
• Subcutaneous Infliximab After A Previous Intravenous Dose Optimization
  NCT06113913 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• TDM-based Infliximab Treatment for Active Perianal Fistulizing Crohn's Disease
  NCT06051253 · Phase: Phase 4 · Ages: 19 Years to 80 Years · Sex: All (male and female) · 1 location
• TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal Response
  NCT07510191 · Phase: Phase 4 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
  NCT06257706 · Phase: Phase 4 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 69 locations

Common questions

What does Phase 4 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.